NCT06818266View on ClinicalTrials.gov

Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

July 31, 2027

Conditions
Sickle Cell DiseaseAcute Chest Syndrome
Interventions
DRUG

Tocilizumab (RoActemra®, 20 mg/mL).

One single intravenous infusion at 8 mg/kg (up to a maximum of 800 mg) for patients ≥ 30 kg and 12 mg/kg for patients \< 30 kg

DRUG

Placebo (NaCl 0.9%)

One single intravenous infusion

Trial Locations (1)

75015

Department of General Pediatrics and Sickle Cell Center, Necker-Enfants malades Hospital, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER